# Retatrutide’s three receptors

> Retatrutide’s three receptors — GLP1 Me — GLP1 Me follows retatrutide into GLP-1, GIP and glucagon receptor experiments, including an awkward result in mice lacking a functional GLP-1 receptor.

There is GLP-1 in the site’s name, and more than GLP-1 in this molecule. A mouse experiment makes the extra company especially interesting.

## GLP-1, GIP and glucagon

The [structural and receptor study](https://pubmed.ncbi.nlm.nih.gov/39019866/) examined retatrutide at GLP-1, GIP and glucagon receptors using receptor complexes and cell-based signalling assays. An agonist is a molecule that activates a receptor; here, the activity reaches across all of these targets.

The activities were unequal when compared with the corresponding native hormones. The unevenness appeals to me. Saying triple agonist names a set of targets, while the receptor experiments begin to describe how differently the molecule behaves at each. Dinner gives the site a subject; this is some of the chemistry underneath it.

These are laboratory measurements of receptor behaviour. Assigning any receptor a numerical share of the hunger described in an interview would be an enormous leap.

## Mice without the GLP-1 receptor

An especially striking [experiment in obese mice lacking a functional GLP-1 receptor](https://pubmed.ncbi.nlm.nih.gov/41997446/) reported that retatrutide normalised body weight. The work found that combined GIP and glucagon receptor agonism could reduce excess body weight in those mice without GLP-1 receptor activity.

That is wonderfully awkward for a site with GLP-1 in its name. The other receptors have earned their full names and some space. The finding belongs to an engineered mouse model; it leaves the explanation of a human response open.

This is the sort of awkward finding I enjoy: the simple story gets harder to maintain. The interviews concern human eating. The mouse experiment concerns what receptor activity can accomplish in a particular animal model. Following both makes the appetite story richer, I think.

## Energy expenditure

A [mechanistic review of combined GLP-1, GIP and glucagon agonism](https://pubmed.ncbi.nlm.nih.gov/39592891/) describes complementary central nervous system and fat-tissue actions, alongside the contribution of glucagon receptor activity to energy expenditure, the energy the body uses. Its account draws together human and preclinical evidence.

The result is a wider biological argument than eating less alone. It also returns the practical question to dinner: how do the different biological contributions relate to the experiences people value at a meal? A receptor assay cannot hold that conversation. The [appetite interviews](/appetite) can at least begin it.

---

GLP-1 Me is my table for published research on appetite, not a business or a source of medical advice.